{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:36:00Z","timestamp":1789821360093,"version":"4.0.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/ftd.0b013e3181d925bb","type":"journal-article","created":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T03:38:53Z","timestamp":1270784333000},"page":"338-345","source":"Crossref","is-referenced-by-count":33,"title":["Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study"],"prefix":"10.1097","volume":"32","author":[{"given":"Gwendolyn A","family":"McMillin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell G","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C","family":"Pendleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210129","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"R2-21-20210129","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1309\/1E34UAPR06PJ6HML","article-title":"Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.","volume":"129","author":"King","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"R4-21-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.tpj.6500417","article-title":"Pharmacogenetics of warfarin: current status and future challenges.","volume":"7","author":"Wadelius","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"R5-21-20210129","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation.","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-21-20210129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/14622416.8.7.851","article-title":"Use of genetic and nongenetic factors in warfarin dosing algorithms.","volume":"8","author":"Wu","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R7-21-20210129","first-page":"183","article-title":"Periprocedural anticoagulation management in orthopedic patients: overview and description of a program utilizing pharmacogenetics.","volume":"15","author":"Grice","year":"2008","journal-title":"J Clin Outcomes Manage"},{"key":"R8-21-20210129","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data.","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-21-20210129","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1538-7836.2008.03074.x","article-title":"Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes.","volume":"9","author":"Thacker","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R10-21-20210129","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/j.1538-7836.2008.03073.x","article-title":"Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.","volume":"9","author":"Mannucci","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R11-21-20210129","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1373\/clinchem.2008.115972","article-title":"Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time.","volume":"55","author":"Eby","year":"2009","journal-title":"Clin Chem"},{"key":"R12-21-20210129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1373\/clinchem.2008.115964","article-title":"Point: use of pharmacogenetics in guiding treatment with warfarin.","volume":"55","author":"Wadelius","year":"2009","journal-title":"Clin Chem"},{"key":"R14-21-20210129","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"R15-21-20210129","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch Intern Med"},{"key":"R16-21-20210129","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.2106\/00004623-200211000-00013","article-title":"Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty.","volume":"84-A","author":"Anderson","year":"2002","journal-title":"J Bone Joint Surg Am"},{"key":"R17-21-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.arth.2006.03.006","article-title":"The effectiveness of warfarin dosing from a nomogram compared with house staff dosing.","volume":"22","author":"Asnis","year":"2007","journal-title":"J Arthroplasty"},{"key":"R18-21-20210129","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-138-9-200305060-00007","article-title":"Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.","volume":"138","author":"Kovacs","year":"2003","journal-title":"Ann Intern Med"},{"key":"R19-21-20210129","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1161\/CIRCULATIONAHA.107.737312","article-title":"Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"R20-21-20210129","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.","volume":"84","author":"Gage","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R21-21-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.clpt.6100316","article-title":"CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.","volume":"83","author":"Caraco","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R22-21-20210129","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting.","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"R23-21-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.GIM.0000153664.65759.CF","article-title":"CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.","volume":"7","author":"Sanderson","year":"2005","journal-title":"Genet Med"},{"key":"R24-21-20210129","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.5858\/2004-128-1360-EOPITC","article-title":"Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.","volume":"128","author":"Adcock","year":"2004","journal-title":"Arch Pathol Lab Med"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181d925bb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:01Z","timestamp":1786040041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201006000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181d925bb","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}